Araştırma Makalesi

Bupropionun visseral ağrı üzerindeki antinosiseptif etkisi ve etki mekanizması

Cilt: 49 Sayı: 2 30 Haziran 2024
PDF İndir
EN TR

Antinociceptive effect of bupropion on visceral pain and its mechanism of action

Abstract

PPurpose: Bupropion is an antidepressant that inhibits noradrenaline and dopamine reuptake. In the current scientific literature, there is limited information regarding the effects of bupropion on pain, predominantly derived from somatic pain studies. This study aims to investigate the impact of bupropion for the first time in visceral pain induced by colorectal distension, a pure visceral pain model, and to reveal the role of various receptors involved in pain control in this effect. Materials and Methods: Male Sprague-Dawley rats were used in the study. Visceral pain was assessed by colorectal distension-induced visceromotor response. Bupropion is administered gastrically at 5, 10, 20, and 40 mg/kg doses. The mechanism of action of bupropion at the spinal cord level was investigated by intrathecal administration of antagonists of α1 and α2 adrenoceptors (prazosin and yohimbine), D1 and D2 dopamine (SCH 23390 and sulpiride) and opioid receptors (naloxone) 10 minutes before bupropion’s effective dose. Results: Bupropion showed significant antinociceptive effects at 20 and 40 mg/kg intragastric doses; no difference was found between these two doses. Intrathecally administered yohimbine (30 µg/rats), sulpiride (30 µg/rats, i.t.), and naloxone (2.5 µg/rats) diminished the antinociceptive effect of bupropion. Prazosin and SCH 23390 did not alter bupropion’s effect. Conclusion: The findings show the antinociceptive effect of bupropion in visceral pain, and adrenergic, dopaminergic, and opioidergic receptors in the spinal cord play a role in this effect.

Keywords

Antidepressant , Bupropion , visceral , pain , visceromotor

Kaynakça

  1. Mico J, Ardid D, Berrocoso E, Eschlier A. Antidepressants and pain. Trends Pharmacol Sci. 2006;27:348–54.
  2. Obata H. Analgesic mechanisms of antidepressants for neuropathic pain. Int J Mol Sci. 2017;18:2483.
  3. Hajhashemi V, Minaiyan M, Banafshe HR, Mesdaghinia A, Abed A. The anti-inflammatory effects of venlafaxine in the rat model of carrageenan-induced paw edema. Iran J Basic Med Sci. 2015;18:654–8.
  4. Schwartz ES, Gebhart GF. Visceral pain. In Behavioral Neurobiology of Chronic Pain (Eds BK Taylor, DP Finn): 171-97. Berlin, Springer. 2014.
  5. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry. 2004;06:159–66.
  6. Hajhashemi V, Khanjani P. Analgesic and anti-inflammatory activities of bupropion in animal models. Res Pharm Sci. 2014;9:251–7.
  7. Marinho BG, Miranda LS, da S Costa J, Leitão SG, Vasconcellos ML, Pereira VL et al. The antinociceptive properties of the novel compound (±)-trans-4-hydroxy-6-propyl-1-oxocyclohexan-2-one in acute pain in mice. Behav Pharmacol. 2013;24:10-9.
  8. Isguzar O, Baris S, Bozkurt A, Can B, Bilge S, Ture H. Evaluation of antinociceptive and neurotoxic effects of intrathecal dexmedetomidine in rats. Balkan Med J. 2012;29:354
  9. Bilge SS, Ilkaya F, Darakcı Ö, Çiftcioğlu E, Bozkurt A. Opioid receptors contribute to antinociceptive effect of tianeptine on colorectal distension-induced visceral pain in rats. Pharmacology. 2017;101:96-103.
  10. Hoshino H, Obata H, Nakajima K, Mieda R, Saito S. The antihyperalgesic effects of intrathecal bupropion, a dopamine and noradrenaline reuptake inhibitor, in a rat model of neuropathic pain. Anesth Analg. 2015;120:460–6.

Kaynak Göster

MLA
Yeşilyurt, İsa, vd. “Antinociceptive effect of bupropion on visceral pain and its mechanism of action”. Cukurova Medical Journal, c. 49, sy 2, Haziran 2024, ss. 415-23, doi:10.17826/cumj.1429753.